Minocycline foam - Foamix

Drug Profile

Minocycline foam - Foamix

Alternative Names: FMX 101; FMX 102; FMX 103; FXFM-244

Latest Information Update: 06 Dec 2016

Price : $50

At a glance

  • Originator Foamix
  • Class Amides; Antibacterials; Dimethylamines; Neuroprotectants; Small molecules; Tetracyclines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Acne vulgaris
  • Phase II Impetigo; Rosacea

Most Recent Events

  • 28 Nov 2016 Foamix Pharmaceuticals completes enrolment in its phase III trial for Acne vulgaris in USA
  • 30 Sep 2016 Foamix completes a phase II trial in Rosacea in Germany (NCT02601963)
  • 12 Sep 2016 Top-line efficacy and adverse events data from a phase II trial in Rosacea released by Foamix Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top